RBC Capital expects the launch of Pharmacyclics' Imbruvica to exceed expectations, and the firm raised its price target on the shares to $150 from $125. It keeps an Outperform rating on the stock.
Sentiment: Strong Buy
150 thats it? we need a 200 target to get this to new highs
patents is a virtue.Pharmacyclics has a very bright future ahead